National Association of Registered Social Security Analysts survey finds alarming trend: 73.5% of advisors report clients requesting early claims specifically because they fear future benefit cuts; 58.8% doubt Congress will act to fix solvency: Early claiming at 62 locks in permanent 30% benefit reduction vs. waiting to full retirement age — despite worse lifetime outcome, panic over potential 22% automatic cut in Q4 2032 pushing people into irreversible decisions — Martha Shedden (NARSSA cofounder): retirees hearing headlines think "I need my money now" — 62.4% of clients feel "overwhelmed by conflicting advice" when weighing claiming age.

Broader education gap limits informed decision-making: 58% don't understand ex-spousal benefits; similar share confuses spousal/survivor benefits; only 1/3 understand how other income affects taxability; nearly half blindsided by Medicare premium impact on monthly checks: INCOME-related monthly adjustment amount (IRMAA) deductions top reason clients receive lower-than-expected payments — knowledge gaps compound panic-driven early claiming decisions — many sacrificing $100K+ in lifetime income due to misconceptions rather than financial necessity.

Shedden pushes back on "blame the boomers" narrative: declining birth rates (3.6 children per woman in 1960 vs. 1.6 in 2024) and disappearance of employer pensions (40% private workers had pensions in 1970s vs. 15% today) primary culprits, not generational hoarding: Multiple modest fixes available (adjust payroll tax cap, change benefit formula, alter retirement age) without requiring dramatic single measure — expert remains confident Congress will act despite gridlock — warns dismissing program as replacement with "Trump accounts" would trigger "huge uproar."

Social Security proves dramatically more efficient than private 401(k) retirement accounts: SSA spends $4.3B administering $1.44 trillion in annual benefits (0.3% cost rate) vs. typical 401(k) expense ratios of 1%+ annually: To replace just $500B in annual Social Security benefits through 401(k)s at 4% real returns would require $12.5 trillion in assets; at 1% annual costs, that's $125B yearly vs. $1.5B through Social Security — private system would cost 83 times more for identical benefit delivery — economist Dean Baker argues efficiency gap exposes that privatization advocates prioritize financial industry profits over cost-effective retirement security.

Massive cost gap stems from fundamental system differences: Social Security spreads administrative overhead across massive centralized system, while 401(k)s impose expenses on individual accounts and fund management fees: Index fund fees lower than actively managed funds (0.5-1.0%+), but even lowest-cost options far exceed Social Security's centralized efficiency — privatization would transfer $100+ billion annually from beneficiaries to financial intermediaries in pure overhead waste, regardless of investment performance.

Argument against "neoliberal efficiency" rationale: if conservative critics truly prioritized efficiency, they would defend Social Security as gold standard for cost-effective retirement delivery — instead, criticism reveals financial industry capture of policy debate: Baker highlights that Wall Street gains $100B+ annually from privatization proposals while workers lose security and guarantees — demonstrates that cost-cutting rhetoric masks wealth transfer agenda disguised as reform.

HHS Office of Inspector General audit found Medicare Part D paid $587.7 million (2021-2023) for five drugs switched from prescription-only to over-the-counter status more than one year prior: CMS used outdated FDA data when updating drug formulary files, creating one-year delay between FDA switching drugs and CMS notifying Medicare Advantage/prescription drug plans to stop covering them — payments increased annually: $184M (2021), $194.54M (2022), $209.14M (2023) — generic Voltaren (topical arthritis pain treatment) accounted for $562.1 million after 15.8 million prescriptions written.

Other affected drugs included Pataday/Lastacaft eye drops (itching/redness), Astepro nasal spray (allergies), and Sklice topical lotion (lice) — structural oversight failure rather than individual fraud: CMS failed to set timeframes requiring plans to reject OTC drug payments — FDA required manufacturers to update labeling within six months of switching drugs to over-the-counter; CMS had no similar enforcement deadline — watchdog recommended CMS align guidance with FDA's six-month policy going forward.

Improper payments straining Medicare finances already facing 2033 trust fund depletion — CMS agreed to tighten oversight and issue guidance to Part D sponsors: Beneficiaries not affected directly since Part D is federally funded program, but overpayments worsen long-term solvency concerns — prevents government from allocating resources to other beneficiary needs — part of broader Trump administration crackdown on healthcare waste/fraud across Medicare, Medicaid programs.